Total: $354.88M | ||||
Company |
Type Of Financing (M) |
Number Of Shares, Units Or Warrants |
Amount Raised (M) |
Investors; Placement Agents;Details |
| | ||||
Alizyme plc (UK; LSE:AZM) |
Private placement of stock |
6.84S |
£11.5 US$19.6 |
Alizyme placed 6.84M shares with institutional investors; Nomura International plc was the placement agent (10/22) |
|
||||
AltaRex |
Private placement of stock |
6U |
C$2.04 (US$1.56) |
AltaRex raised about C$2M through the sale of 6M units, each consisting of one share and one warrant to purchase one share at C$0.50 each (10/21) |
|
||||
Alteon Inc. |
Private placement of stock |
4.46S |
$7.8 |
Alteon raised about $7.8M through the sale of shares to institutional investors at $1.75 each; investors have the option to purchase another 1.56M shares at $1.85 each (10/16) |
|
||||
Ariad Pharmaceuticals |
Private placement of stock |
6.44S |
$41 |
Ariad raised $41M though the placement of 6.44M shares covered under a shelf registration statement; Lehman Brothers and Rodman & Renshaw were placement agents (10/03) |
|
||||
CollaGenex |
Private placement of stock |
2S |
$20 |
CollaGenex grossed $20M from the placement of 2M shares that were covered under a registration statement; Rodman & Renshaw and Jessup and Lamont were placement agents (10/3) |
|
||||
Cytomedix |
Private placement of stock |
ND |
$2.5 |
Cytomedix raised $2.5M in a private stock sale; financial terms were not disclosed (10/9) |
|
||||
Endovasc Inc. |
Private placement of stock |
ND |
$1.2 |
Endovasc said it received $1.2M in proceeds from the sale of stock to foreign investors (10/16) |
|
||||
Genaissance |
Private placement of preferred stock |
0.27S |
$6.1 |
Genaissance sold shares of Series A preferred stock that can be converted into 2.7M common shares; they pay a cash dividend of 2 percent; RAM Trading Ltd. also got warrants for another 190,000 Series A shares (10/30) |
|
||||
Genaissance |
Term loan |
N/A |
$5 |
Genaissance got a three-year, $5M term loan with Comerica Bank to repay existing capital leases (10/30) |
|
||||
Genelabs |
Firm- commitment deal |
23S |
$31.5 |
Genelabs priced an offering of 20M shares at $1.37 per share in a firm-commitment underwriting deal, under which Natexis Bleichroeder Inc. bought the shares directly and is responsible for any credit risk; Natexis purchased 3M shares as part of an overallotment option (10/17) |
|
||||
Genetronics |
Private, milestone-driven investment |
ND |
$7.5 |
Genetronics received a $7.5M second tranche of funding from a financing that totals $15.7M, after meeting milestones related to MedPulser development; SCO Securities LLC was placement agent (10/22) |
|
||||
GenoMed |
Bridge funding |
ND |
$0.12 |
GenoMed secured bridge funding of up to $420,000 per month, of which $100,000 is guaranteed, through October 2004 (10/22) |
|
||||
Genome Therapeutics Corp. (GENE) |
Private placement of stock |
5.2S and 2.6W |
$13 |
Genome Therapeutics raised $13M through two closings of a private placement; the five-year warrants are exercisable at $3.48 per share; Life Science Group was placement agent (10/16) |
|
||||
Hermispherx Biopharma Inc. (AMEX:HEB) |
Private placement of convertible debentures |
N/A |
$4.1 |
Hemispherx sold 6% convertible debentures due Oct. 30, 2005; warrants equaling 20% of the offering and convertible at $2.32 per share also were issued; Cardinal Securities LLC was placement agent (10/30) |
|
||||
ID Biomedical Corp. (Canada; IDBE) |
Bought-deal financing |
5.8U |
$100 |
Investors agreed to pay $17.37 per unit, which consists of one common share and one-half of one common share purchase warrant to purchase a full share at $25 (10/9) |
|
||||
IntraBiotics Pharmaceuticals Inc. (IBPI) |
Private placement of stock |
1.774S and 0.355W |
$19.2 |
IntraBiotics raised $19.2M through the sale of 1.774M shares and warrants to purchase 355,000 shares at $10.85 per share; Lazard Freres and Co. and WR Hambrecht + Co. were advisers (10/6) |
|
||||
Matritech Inc (NMPS) |
Private placement of stock |
3.6S and 1.26W |
$6 |
Matritech raised $6M in the sale to undisclosed investors; the warrants carry an exercise price of $2.45 per share (10/15) |
|
||||
Nuvelo Inc. (NUVO) |
Private placement of stock |
11.5S |
$28.2 |
Nuvelo raised $28.2M through the private sale of 11.5M shares, including the overallotment option; JMP Securities LLC was the underwriter (10/2) |
|
||||
Oncolytics Biotech Inc. (Canada; ONCY) |
Bought-deal financing |
1.2S and 0.6W |
$6 |
Oncolytics sold 1.2 million units, each consisting of one common share and a warrant for one-half of one share; Canaccord Capital underwrote the deal (10/14) |
|
||||
Progen Industries Ltd. (Australia; PGLAF) |
Private placement of stock |
3.8S |
A$5.8 (US$4.1) |
Progen sold 3.8M shares at A$1.40 each after re-negotiating terms of the placement with Taylor Collision Ltd. (10/31) |
|
||||
Pro-Pharmaceuticals Inc. (AMEX:PRW) |
Private placement of stock |
1.3S and 0.65W |
$4.6 |
Pro-Pharmaceuticals raised $4.6M through the sale of 1.3M shares and warrants to purchase up to 650,000 more shares; Rodman & Renshaw was placement agent (10/3) |
|
||||
SIGA Technologies Inc. (SIGA) |
Private placement of stock |
6.5S and 3.1W |
$9 |
SIGA is raising $9 million through the sale of stock to MacAndrews & Forbes Holdings Inc. and affiliates of TransTech Pharma Inc.; warrants are exercisable at $2 per share (10/8) |
|
||||
The Immune Response Corp. (IMNR) |
Private placement of stock |
6S and 3W |
$12 |
Immune Response sold 6 million shares at $2.02 and issued 3M warrants exercisable at $3.32 per share; Rodman & Renshaw Inc. was placement agent (10/14) |
|
||||
Viragen Inc. (AMEX:VRA) |
Private placement of stock |
21.3S and 4.26W |
$4.8 |
Viragen raised $4.8M through the sale of about 21.3M shares at $0.224 per share, and issued 1.4M shares and warrants for 0.191M shares as a fee to the transaction's finder (9/29) |
| | ||||
Notes: | ||||
|
||||
This chart does not include real estate or manufacturing plant financings. | ||||
One entry occurred in September but was not included in that chart. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
